News

Setting the path towards fair medicine prices 06-07-2020

 
Pharma_pricing.jpg

Joint statement of EU public health stakeholders

Current pharmaceutical prices are set at levels that come at the expense of the access for patients and the sustainability of healthcare systems. As a result, a reflection on fair medicines has gained traction over the past years. A coalition of 12 European and international organisations, including ESIP, put forward recommendations for the EU to reach fairer drug pricing.

Fighting anti-microbial resistance 23-06-2020

 
AMR_banner.jpg

A dual approach to protect public health

Antimicrobial resistance (AMR), defined as “the ability of a microorganism to stop an antimicrobial from working against it”[i], is a growing global public health threat, with 30 000 patients in the EU dying annually as a result of infections caused by resistant bacteria, while antibiotic consumption in the EU almost doubled between 2010 and 2014[ii]. The European Commission is launching discussions on ways to tackle AMR and to address the lack of new antimicrobials, in the context of its upcoming Pharmaceutical Strategy for Europe.

As a contribution to this discussion, the European Social Insurance Platform (ESIP) representing the statutory social insurances in 17 Member States, the United Kingdom and Switzerland, would like to raise awareness amongst decision-makers of the importance of tackling the spread of AMR by improving infection prevention and control as well as increasing the development and availability of new effective antimicrobials inside and outside the EU.

COVID-19 & social security 25-05-2020

 
Umbrellas.png

Safeguarding public health & social protection in times of pandemic

The coronavirus pandemic is an unprecedented challenge for the health and social security systems in the European Union. Social security systems play a key role in providing healthcare, sickness benefits, unemployment benefits and much more to insured persons, during this pandemic and beyond. By implementing several measures such as simplifying procedures to access benefits and providing additional benefits to those most affected, ESIP members have shown their flexibility and ability to cope with the current situation.

COVID-19: Joint letter to the European Commission 19-03-2020

 
coronavirus.PNG

Statement on the current developments of the COVID-19 pandemic

On 18th March 2020, the European Social Insurance Platform (ESIP) signed a joint letter addressed to the European Commission on the response at EU level to the Coronavirus (COVID-19) pandemic. The statement was co-signed by AIM (the International Association of Health Care Mutuals and Health Care Funds), CPME (Standing Committee of European Doctors) and HOPE (the European Hospital and Healthcare Federation).

ESIP, together the with co-signatories, welcome the ‘Corona Response Investment Initiative’ and offer their full support on the European Union’s efforts to fight against the COVID-19 pandemic. While slowing down the spread of the virus, it is essential to ensure that healthcare professionals have access to suitable equipment and that patients receive appropriate treatment.  The discussion against vital medicine shortages in Europe remains important, in particular Europe’s dependency on single sourcing in the production and distribution chain of pharmaceuticals and medical devices.

As European level representatives of the health care community, ESIP, AIM, CPME and HOPE remain at the disposal of the European Commission to provide any information and support they can in tackling this and similar health threats in the future.

Find out more in the statement.